Related Experiment Video
Updated: Jul 29, 2026
09:56
In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
Published on: January 21, 2018
[Dexmedetomidine, a promising drug]
1Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Hospital Universitario Puerta del Mar, Cádiz.
Revista Espanola De Anestesiologia Y Reanimacion
|November 29, 2002
Summary
Dexmedetomidine offers sedation and pain relief for surgical patients, reducing the need for other anesthetics and analgesics. This imidazole-derived drug targets alpha-2 adrenoreceptors, showing promise in intensive care settings.
Area of Science:
- Pharmacology
- Anesthesiology
- Critical Care Medicine
Context:
- Intensive care units (ICUs) and recovery rooms require effective sedation and pain management for surgical patients.
- Existing pharmaceutical options for sedation and analgesia have limitations and varying degrees of use.
- Dexmedetomidine, an alpha-2 adrenoreceptor agonist, is under investigation for its therapeutic potential in these settings.
Purpose:
- To review the pharmacological properties, pharmacokinetics, and pharmacodynamics of dexmedetomidine.
- To evaluate the efficacy and safety of dexmedetomidine in clinical trials for sedation and analgesia.
- To provide a comprehensive overview of dexmedetomidine as a promising therapeutic agent.
Summary:
- Dexmedetomidine, a potent alpha-2 adrenoreceptor agonist, exhibits sedative, hypnotic, and analgesic properties.
- Clinical studies demonstrate that dexmedetomidine reduces the requirement for other sedatives (e.g., propofol, midazolam) and analgesics (e.g., morphine).
- It has minimal impact on ventilation and reduces the need for additional anesthetics and sympathicolytics by decreasing catecholamine release.
Impact:
- Dexmedetomidine offers a potentially advantageous alternative for sedation and analgesia in postoperative care.
- Its favorable pharmacological profile may lead to reduced polypharmacy and improved patient outcomes in ICUs.
- Further research and wider clinical adoption, including in the European Union, could enhance its role in critical care medicine.
Related Concept Videos
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:24Parenteral Anesthetics: Overview
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
01:23Sedatives and Hypnotics: Overview
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:20Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...